# Kiadis Pharma to present at the American Society of Hematology 2019 Annual Meeting

ASH Abstract #

**ATIR101:** 592, 4464; **NK-cell Therapy (K-NK002)** 1955

- Phase II data analysis of ATIR101 as an adjunctive treatment following T-cell depleted haploidentical hematopoietic stem cell transplantation
- Trial-in-progress overviews of Phase III ATIR101 and Phase II NK-cell Therapy (K-NK002) clinical trial programs

**Amsterdam, The Netherlands, November 6, 2019 – Kiadis Pharma N.V. (Euronext Amsterdam and Brussels: KDS)**, a clinical stage biopharmaceutical company, today announces abstracts showcasing the potential of the company's pipeline therapies, (ATIR101 and K-NK002), will be presented at the 59th Annual Meeting of the American Society of Hematology (ASH) taking place December 7–10 in Orlando, Florida.

New ATIR101 data will be discussed in an oral presentation exploring the effect of a single infusion of ATIR101 on survival outcomes in patients with blood cancer (including acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], and myelodysplastic syndromes [MDS]) who underwent T-cell depleted haploidentical-hematopoietic stem cell transplantation (haplo-HSCT) from a pooled analysis of two Phase II trials (CR-AIR-007, NCT01794299; CR-AIR-008, NCT02500550). Additionally, a trial-in-progress (TIP) overview of the global, randomized ATIR101 Phase III trial (NCT02999854) will be presented, describing the head-to-head comparison of outcomes of patients who receive ATIR101 after T-cell depleted haplo-HSCT compared to the commonly applied approach of using post-transplant chemotherapy with cyclophosphamide (PTCy) in patients who have received a T-cell replete haplo-HSCT.

Kiadis Pharma will also provide a TIP overview of the multi-center Phase II trial (BMT CTN 1803) evaluating the efficacy of K-NK002, Kiadis Pharma's recently acquired adjunctive immunotherapeutic, in decreasing risk of relapse in patients with high-risk AML or MDS undergoing haplo-HSCT.

"Our presence at ASH demonstrates our long-term commitment to developing personalized, next-generation cell therapies for some of the hardest to treat blood cancers," said Arthur Lahr, CEO of Kiadis Pharma. "By applying highly innovative science in our clinical programs, we believe our pipeline has potential to bring us closer to addressing critical unmet needs, not just for patients, but for the healthcare professionals that treat them."

***Kiadis Contacts:***

**Kiadis Pharma**:
Maryann Cimino, Manager, Corporate Affairs
Tel: +1 (617) 710-7305
m.cimino@kiadis.com

**Kiadis Pharma Company Abstracts at ASH 2019**

| Medicine | Abstract Number | Lead Author | Abstract Title | Presentation Type | Presentation time |
|---|---|---|---|---|---|
| **ATIR101** | 592 | Denis Claude Roy | Addition of ATIR101, an Adjunctive Treatment following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors | Oral | Session Name: 711. Cell Collection and Processing<br>Session Date: Monday, December 9, 2019<br>Session Time: 7:00 AM - 8:30 AM<br>Presentation Time: 7:45 AM<br>Room: Orange County Convention Center, W414AB |
| | 4464 | Denis Claude Roy | Head-to-Head Comparison of Haploidentical HSCT Strategies for Hematologic Malignancies: Phase III HATCY Study of T-Cell-Depleted HSCT with Adjunctive ATIR101 versus T-Cell-Replete HSCT with Post-Transplant Cyclophosphamide | Poster | Session Name: 704. Immunotherapies: Poster III<br>Date: Monday, December 9, 2019<br>Presentation Time: 6:00 PM - 8:00 PM<br>Location: Orange County Convention Center, Hall B |
| **K-NK002 (Previously CSTD002)** | 1955 | Sumithira Vasu | BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-transplant Relapse in AML and MDS (NK-REALM) | Poster | Session Name: 704. Immunotherapies: Poster I<br>Date: Saturday, December 7, 2019<br>Presentation Time: 5:30 PM - 7:30 PM<br>Location: Orange County Convention Center, Hall B |

**About ATIR101 and K-NK002**

Administered as adjunctive immunotherapeutics on top of HSCT, ATIR101 and K-NK002 provide lymphocyte infusions with functional, mature and potent immune cells from a haploidentical family member. The T-cells in ATIR101 and NK-cells in K-NK002 will help fight infections and remaining

tumor cells, until the immune system has fully re-grown from stem cells in the transplanted graft. In addition, K-NK002 has shown promise in the treatment of relapse/refractory AML.

In ATIR101, T-cells that would cause GVHD are depleted from the donor lymphocytes, using our photodepletion technology. At the same time, ATIR101 contains potential cancer-killing T-cells from the donor that could eliminate residual cancer cells and help prevent relapse of the disease. Furthermore, the donor lymphocytes retain their immune function and help protect the patient from infection.

In K-NK002, nanoparticle processing technology enables improved *ex vivo* expansion and activation of NK-cells supporting multiple high-dose infusions with potent anti-cancer cytotoxicity.

**About Kiadis**
Founded in 1997, Kiadis Pharma, is a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life threatening diseases. With headquarters in Amsterdam, the Netherlands, and offices in the US and across Europe, Kiadis Pharma is leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.kiadis.com.

**Forward Looking Statements**
*Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma's or, as appropriate, Kiadis Pharma's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.*